Results 141 to 150 of about 17,066 (197)

Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis. [PDF]

J Int Med Res
Yuan D, Cheng T, Cao Z, Wang F, Wang Y.
europepmc   +1 more source

Successful use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Hypertriglyceridemia-induced Acute Pancreatitis: A Case Report. [PDF]

Curr Cardiol Rev
Qi R, Liu H, Li X, Chen M.
europepmc   +1 more source

Association between statin discontinuation after proprotein convertase subtilisin/kexin type 9 inhibitor initiation and subsequent atherosclerotic cardiovascular disease events. [PDF]

J Manag Care Spec Pharm
Peasah SK, Lee T, Do D, Huang Y, Inneh A, Patel U, Aiyer AN, Good CB.   +7 more
europepmc   +1 more source

Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Primary Cardiovascular Prevention in High-Risk Patients: A Systematic Review. [PDF]

Cureus
Khan S, Asif A, Omer O, Gondal MZD, Tallal H, Abbas T.   +5 more
europepmc   +1 more source

Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis. [PDF]

Malays J Med Sci
Matin A, Chaudhry GE, Azra MN, Gazali M, Yeong YS, Tengku Muhammad TS.   +5 more
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm. [PDF]

Curr Opin Lipidol
Golledge J, Lu HS, Shah S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Proprotein convertase activation of aggrecanases in cartilage in situ

Archives of Biochemistry and Biophysics, 2008
Proteolytic degradation of the major cartilage macromolecules, aggrecan and type II collagen, is a key pathological event in osteoarthritis (OA). ADAMTS-4 and ADAMTS-5, the primary aggrecanases capable of cartilage aggrecan cleavage, are synthesized as latent enzymes and require prodomain removal for activity.
Anne-Marie Malfait, Micky D Tortorella, Elizabeth C Arner   +2 more
exaly   +3 more sources

Proprotein convertases as therapeutic targets

Expert Opinion on Therapeutic Targets, 2008
Limited endoproteolysis of precursor proteins is a common mechanism of production of functional proteins and peptides. In the secretory pathway of eukaryotic cells, this endoproteolysis is principally mediated by a family of calcium-dependent serine proteases, generically known as proprotein convertases.
Michel, Chrétien, Nabil G, Seidah, Ajoy, Basak, Majambu, Mbikay   +3 more
openaire   +2 more sources

Proprotein Convertases in Health and Disease

New England Journal of Medicine, 2011
Proteases that process larger precursor proteins into smaller functional proteins are involved in a wide range of physiologic processes. Derangements in the function of these enzymes play a role in many diseases.
Andrew W, Artenstein, Steven M, Opal
openaire   +2 more sources

The proprotein convertases

Current Opinion in Chemical Biology, 1998
The major endoproteolytic processing enzymes of the secretory pathway are the subtilisin-like proprotein convertases (SPCs). Furin (SPC1) has emerged as one of the major processing enzymes of the constitutive secretory pathway and its localization in the trans-Golgi network and mechanism of autoactivation have been studied in considerable detail ...
openaire   +2 more sources